TY - JOUR AU - Kosmidis, Christoforos AU - Sapalidis, Konstantinos AU - Kotidis, Efstathios AU - Mixalopoulos, Nikolaos AU - Zarogoulidis, Paul AU - Tsavlis, Drosos AU - Baka, Sofia AU - Man, Yan-Gao AU - Kanellos, John PY - 2016 TI - Pancreatic cancer from bench to bedside: molecular pathways and treatment options JF - Annals of Translational Medicine; Vol 4, No 9 (May 17, 2016): Annals of Translational Medicine (Focus on Surgical Techniques from Bench to Bedside) Y2 - 2016 KW - N2 - In the last forty years the pancreatic cancer treatment has made advances, however; still novel drugs are needed. It is known that the five year survival rate remains around 5%. The best treatment option still remains surgery, if patients are diagnosed early. In the last decade the biology of pancreatic cancer has been vastly explored and novel agents such as; tyrosine kinase agents, or vaccines have been added as a treatment perspective. The big challenge is now to translate this knowledge in better outcomes for patients. In this current review we will present information from pancreatic cancer diagnosis to molecular pathways and treatment options; current and future. UR - https://atm.amegroups.org/article/view/10412